Mirum Pharmaceuticals, Inc. Current Assets
Mirum Pharmaceuticals, Inc. (MIRM) had Current Assets of $636.31 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-05
- 2026-06-30: Assets, Current $636.31M.
- 2026-03-31: Assets, Current $569.44M.
- 2025-12-31: Assets, Current $549.68M.
- 2025-09-30: Assets, Current $530.58M.
| Period end | Assets, Current |
|---|---|
| 2026-06-30 | $636.31M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $569.44M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $549.68M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $530.58M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $453.40M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $410.82M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $392.79M 10-K · filed 2026-02-25 |
| 2024-09-30 | $386.63M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $367.83M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $389.46M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $387.54M 10-K · filed 2025-02-26 |
| 2023-09-30 | $388.58M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $383.52M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $172.33M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $190.22M 10-K · filed 2024-03-15 |
| 2022-09-30 | $215.56M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $147.25M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $155.27M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $166.59M 10-K · filed 2023-03-08 |
| 2021-09-30 | $196.81M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $228.37M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $217.75M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $236.35M 10-K · filed 2022-03-09 |
| 2020-09-30 | $138.15M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $152.07M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $162.44M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $119.36M 10-K · filed 2021-03-09 |
| 2019-09-30 | $129.32M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $84.86M 10-Q · filed 2019-08-28 |
| 2018-12-31 | $51.98M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |